홈

규제 업데이트

FDA, EMA, TGA 및 글로벌 규제 동향

UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
FDA Grants ANDA Approval for Atomoxetine Capsules by Strides Pharma
The FDA approved ANDA 079021 for atomoxetine hydrochloride capsules from Strides Pharma Science, covering strengths from 10 mg to 100 mg.
1
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
MFDS Marks ‘Cosmetics Day’ with K‑Beauty Showcase, Emphasizes Global Growth
South Korea’s Food and Drug Safety Administration held a ceremony on Sep 7 to celebrate ‘Cosmetics Day’, highlighting K‑beauty achievements and promoting safety and global competitiveness.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
World’s First Global Cosmetics Regulatory Agency Platform Launched in Seoul
The Global Cosmetics Regulatory Agency Council (GCORAS) was officially inaugurated in Seoul, led by South Korea’s Ministry of Food and Drug Safety, with meetings running through Sept 9.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
FDA Approves Hikma’s Indomethacin Sodium Injection (ANDA 078713)
The FDA has approved ANDA 078713 for Hikma’s injectable Indomethacin Sodium, though the product is listed as discontinued.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
FDA Approves ANDA078416 for Prednisolone Sodium Phosphate Oral Solution
The FDA granted approval (status AP) for Vintage Pharms' ANDA078416 covering an oral solution of prednisolone sodium phosphate on Oct 31 2007; the product is listed as discontinued.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
GE Healthcare alerts on exposed sharp edge in SIGNA™ Artist cabinets
GE Healthcare reports an exposed sharp edge inside SIGNA™ Artist and Artist Evo electronics cabinets that may damage power cables and cause an electrical fault or arc flash risk.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
GE Healthcare Alerts on Exposed Sharp Edge in SIGNA™ Artist Cabinets
GE Healthcare reports an exposed sharp edge inside SIGNA™ Artist and Artist Evo electronics cabinets that could damage power cables and cause an arc flash injury.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
Lupin Ltd Submits Original ANDA216716 to FDA – Tentative Approval
Lupin Ltd filed an original ANDA (application number ANDA216716) with the FDA, currently listed as Tentative Approval as of August 13, 2024.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
FDA Grants ANDA216294 Approval for Calcitonin Salmon Injection by Amneal
The FDA has approved the ANDA216294 application for a calcitonin salmon injectable (200 IU/mL) manufactured by Amneal Pharmaceuticals.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
FDA Approves ANDA215856 for Furosemide Injection (10 mg/mL)
The FDA has approved ANDA215856 for a 10 mg/mL furosemide injectable, manufactured by Devatis Inc. and sponsored by Saba Ilac Sanayive.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
FDA Approves AUVELITY Extended-Release Tablet (NDA 215430)
The FDA has approved AUVELITY, an oral extended‑release tablet combining bupropion hydrochloride and dextromethorphan hydrobromide under NDA 215430.
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
HK Innoen’s GERD drug K‑Cap 50 mg earns world’s first EPD for oral solid dosage
HK Innoen’s GERD medication K‑Cap 50 mg became the first oral solid dosage drug globally to receive an Environmental Product Declaration, highlighting its sustainability credentials.